Profound Medical (TSE:PRN) has released an update.
Profound Medical is set to release its third quarter financial results on November 7, inviting investors to a conference call to discuss the details. The company specializes in incision-free medical therapies, including the TULSA-PRO® system for prostate treatment and Sonalleve® for uterine fibroids and bone metastases.
For further insights into TSE:PRN stock, check out TipRanks’ Stock Analysis page.
